Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele

British Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2007, Pages 445-449

  Cui, Yi M ^a   Teng, Choo H ^b   Pan, Alan X ^b   Yuen, Eunice ^b   Yeo, Kwee P ^b   Zhou, Ying ^a   Zhao, Xia ^a   Long, Amanda J ^c   Bangs, Mark E ^c   Wise, Stephen D ^b  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Atomoxetine; Chinese; CYP2D6; CYP2D6*10; Pharmacokinetics

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ALLELE; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; INFORMATION PROCESSING; MALE; METABOLISM; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VITAL SIGN;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PROPYLAMINES;

EID: 34548625125     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02912.x     Document Type: Article

References (10)

1. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with attention-deficit/hyperactivity disorder: two randomised, placebo-controlled studies. Biol Psychiatry 2003 53 : 112 20.
2. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomised, placebo-controlled study. Am J Psychiatry 2002 159 : 1896 901.
3. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002 30 : 319 23.
4. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA. Disposition and metabolic fate of atomoxetine hydrochloride. The role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003 31 : 98 107.
5. Guengerich FP. Human cytochrome P450 enzymes. In : Cytochrome P450: Structure, Mechanism and Biochemistry, Ortiz de Montellano PR. New York : Plenum Press 1995 : 473 535.
6. Ji L, Pan S, Wu J, Marti-Jaun J, Hersberger M. Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J (Engl) 2002 115 : 1780 4.
7. Yin OQP, Shi XJ, Tomlinson B, Chow MS. Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects. Drug Metab Dispos 2005 33 : 1283 7.
8. Honda M, Nozawa T, Igarashi N, Inoue H, Arakawa R, Ogura Y, Okabe H, Taguchi M, Hashimoto Y. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. Biol Pharm Bull 2005 28 : 1476 9.
9. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005 44 : 571 90.
10. Strattera®, PV5311 AMP. Package Insert. Indianapolis, IN : Eli Lilly 2002.